Pfizer to begin testing universal coronavirus vaccines By Tina Reed, author of Axios Vitals Jul 1, 2022 https://www.axios.com/2022/06/30/pfizer-universal-covid-vaccine-testing
Pfizer and its partner BioNTech plan to start clinical trials of pan-coronavirus vaccines in the second half of the year, BioNTech officials said in an investor presentation on Wednesday. The company said it wants to provide "durable variant protection," according to Reuters, which first reported the news. Why it matters: Creating a vaccine that works against a variety of coronaviruses, including COVID-19, represents a holy grail — particularly as new variants threaten to outrun our current arsenal of vaccines. State of play: Universal vaccines have been studied with limited success for years, but they are gaining renewed investment and research interest. * A pan-coronavirus vaccine, being developed at the Walter Reed Army Institute of Research, was planned for a Phase 1 clinical trial in April, CNN reported. * The NIH announced this week the start of a Phase 1 clinical trial to test the safety of a universal flu vaccine candidate, as well as its ability to prompt immune responses. "The scientific community is making progress on this pressing global health priority," said NIAID director Anthony Fauci in a statement. Be smart: As Axios' Caitlin Owens wrote last year, some experts say making a universal coronavirus vaccine may be easier than making a universal flu vaccine, especially given all that's been learned over the last two years. From: Stephen Loosley<mailto:[email protected]> Sent: Tuesday, 21 June 2022 Subject: [LINK] O/t: Each SARS-CoV-2 reinfection causes more severe disease Each SARS-CoV-2 reinfection causes more severe disease By Neha MathurJun 20 2022 Reviewed by Emily Henderson, B.Sc. https://www.news-medical.net/news/20220620/Each-SARS-CoV-2-reinfection-causes-more-severe-disease.aspx In a recent study under review at the Nature Portfolio journal and currently posted to the Research Square* preprint server, researchers at Washington University School of Medicine and the VA Saint Louis Health Care System showed that acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection adds to the risks of all-cause mortality and hospitalization which were accrued during the first SARS-CoV-2 infection. Background Globally, people are acquiring repeat SARS-CoV-2 infections or reinfections. However, studies have not extensively investigated whether reinfection contributes to an increased risk of post-acute sequelae in the pulmonary and extrapulmonary organ systems and even death. Addressing these questions could reduce the overall burden of SARS-CoV-2 infections and inform reinfection mitigation and prevention strategies. About the study In the current study, researchers accessed the United States Department of Veterans Affairs electronic healthcare records (EHRs) to investigate how SARS-CoV-2 reinfection adds to the risk acquired after the first infection. They characterized the risks and 6-month burden of a panel of pre-specified outcomes in a cohort of people with first infection (n = 257,427), reinfection (2 or more infections, n = 38,926), and a non-infected control group (n = 5,396,855) to estimate risks and 6-month burdens of all-cause mortality, hospitalization, and a set of pre-specified incident outcomes. The researchers presented two measures of SARS-CoV-2 reinfection-related risks. First, they assessed the adjusted hazard ratios (HRs) of pre-specified outcomes in re-infected people with those with a first SARS-CoV-2 infection. Second, they assessed the adjusted excess burden of each adverse clinical outcome of coronavirus disease 2019 (COVID-19) per 1,000 persons at six months of reinfection. Lastly, the team performed positive and negative outcome control analyses. The positive outcome control analysis tested the association of a SARS-CoV-2 infection with the risk of fatigue, a well-characterized, key post-acute sequela of COVID-19. In the negative outcome control analyses, the researchers tested the association of a SARS-CoV-2 infection with negative outcome controls, such as atopic dermatitis and neoplasms. Study findings The study population had 257,427 participants who contracted COVID-19 only once and 38,926 participants with two or more SARS-CoV-2 reinfections. In the test group with reinfection cases, 12.29%, 0.76%, and 0.08% of people had two, three, and four or more infections, respectively. The median time distribution between the first-second and second-third infection was 79 and 65 days, respectively. Post-weighting, the standardized mean differences in the participant characteristics, including medications, diagnoses, and laboratory test results, remained balanced in each analysis. Those with reinfections had a higher risk of all-cause mortality, with HR of 2.14 and an excess burden of all-cause mortality of 23.8 per 1000 persons at six months. These individuals also had a higher hospitalization risk, with an HR of 2.98. In addition, people with reinfection exhibited an increased risk of sequelae in the pulmonary and several extrapulmonary organ systems. Accordingly, reinfection increased the risk of adverse health outcomes in people with cardiovascular disorders, kidney problems, gastrointestinal issues, and musculoskeletal and neurological disorders. Overall, reinfection adversely impacted several extrapulmonary organ systems and the pulmonary system. The positive outcome control analysis was based on prior biological and epidemiological evidence. Its results showed that compared to a non-infected control group, those with repeat SARS-CoV-2 infection exhibited an increased risk of fatigue (HR=2.02). Conversely, the risk of atopic dermatitis and neoplasms showed no such association. Furthermore, the time from initial infection to reinfection did not change the association between reinfection and the accrued risks of all-cause mortality, at least one post-acute sequela, and hospitalization, as indicated by the interactions on the multiplicative scale. Conclusions A SARS-CoV-2 reinfection, regardless of a person's vaccination status, increased the risk of all-cause mortality, hospitalization, at least one sequelae, and sequelae in different organ systems compared to the first infection. Although the risks were most pronounced in the acute infection phase, they persisted in the post-acute phase and up to six months for most sequelae. Moreover, the risk and burden of the pre-specified health outcomes increased in a graded fashion, with the lowest risk for people with one SARS-CoV-2 infection and the highest in people with three or more infections. Over half a billion people have been infected with SARS-CoV-2 worldwide at least once. The study findings highlighted that continued vigilance is crucial for these people to reduce the overall risk to one's health. In addition, studies have gathered data that confirms that the reinfection risk is higher with the SARS-CoV-2 Omicron variant. The current study adds to the existing body of evidence, further validating that reinfection adds risk in both acute and post-acute phases among fully vaccinated people. This implies that combined natural and vaccine-induced immunity does not mitigate the risk following SARS-CoV-2 reinfection. In other words, regardless of COVID-19 history and vaccination status, people will need and benefit from reinfection prevention strategies. *Important notice Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information. Journal reference: Outcomes of SARS-CoV-2 Reinfection, Ziyad Al-Aly, Benjamin Bowe, Yan Xie, Research Square 2022, DOI: https://doi.org/10.21203/rs.3.rs-1749502/v1 https://www.researchsquare.com/article/rs-1749502/v1 _______________________________________________ Link mailing list [email protected] https://mailman.anu.edu.au/mailman/listinfo/link _______________________________________________ Link mailing list [email protected] https://mailman.anu.edu.au/mailman/listinfo/link
